major depressive disorder Archives

Neuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology

GERMANTOWN, Md., Feb. 28 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announced the recent publication of preclinical data on NSI-189 in Journal of Cellular Physiology. The study demonstrated that NSI-189 improved behavioral function recovery and enhanced hippocampal synaptic [...]

Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder

GERMANTOWN, Md., Feb. 16 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced completion of subject enrollment in its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder (MDD). NSI-189 is a new [...]